RPS6KA2(RSK3)
Sign in to save this workspaceUniProt Q15349 · PDB · AlphaFold · Substrate: Glycogen Synthase-derived peptide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 98.5% | 1.5% | 82.96 | 0.513 |
| 2 | Midostaurin | 98.5% | 1.5% | 78.64 | 0.500 |
| 3 | Netarsudil | 96.6% | 3.4% | 93.22 | 0.676 |
| 4 | Rabusertib | 91.1% | 8.9% | 98.74 | 0.687 |
| 5 | Sunitinib | 79.5% | 20.5% | 91.73 | 0.524 |
| 6 | Capivasertib | 71.8% | 28.2% | 96.48 | 0.644 |
| 7 | Defactinib | 67.5% | 32.5% | 92.68 | 0.450 |
| 8 | Darovasertib | 66.0% | 34.0% | 96.99 | 0.719 |
| 9 | Ceritinib | 64.7% | 35.4% | 95.44 | 0.618 |
| 10 | Bosutinib | 63.4% | 36.6% | 87.22 | 0.555 |
| 11 | Nintedanib | 57.6% | 42.4% | 90.23 | 0.608 |
| 12 | Repotrectinib | 51.5% | 48.5% | 84.21 | 0.608 |
| 13 | Lazertinib | 50.3% | 49.7% | 97.47 | 0.674 |
| 14 | Axitinib | 49.2% | 50.8% | 93.23 | 0.688 |
| 15 | Selpercatinib | 48.9% | 51.1% | 96.72 | 0.635 |
| 16 | Gilteritinib | 44.1% | 55.9% | 88.97 | 0.506 |
| 17 | Pralsetinib | 39.5% | 60.5% | 93.43 | 0.643 |
| 18 | Paxalisib | 34.1% | 65.9% | 99.75 | 0.609 |
| 19 | Abemaciclib | 27.9% | 72.1% | 91.48 | 0.563 |
| 20 | Osimertinib | 26.4% | 73.6% | 97.24 | 0.733 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.65
- Epithelial log2(TPM+1): 1.99
- Fold change: 1.66
- Status: Upregulated
Selectivity landscape vs inhibition on RPS6KA2
Each point is one of the 92 approved drugs; color = inhibition % on RPS6KA2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…